Loading clinical trials...
Loading clinical trials...
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Andexanet Alfa Administered to Healthy Japanese and Caucasian Subjects
Conditions
Interventions
Andexanet alfa
Apixaban
+3 more
Locations
1
United States
WCCT Global
Cypress, California, United States
Start Date
August 28, 2017
Primary Completion Date
August 13, 2019
Completion Date
August 13, 2019
Last Updated
February 24, 2023
NCT07032792
NCT04645199
NCT06088537
NCT06535568
NCT07333144
NCT03636295
Lead Sponsor
Portola Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions